应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02367 巨子生物
耶稣受难节休市 03-28 16:08:03
42.550
+0.000
0.00%
最高
43.000
最低
41.700
成交量
191.90万
今开
43.000
昨收
42.550
日振幅
3.06%
总市值
423.37亿
流通市值
423.37亿
总股本
9.95亿
成交额
8,147万
换手率
0.19%
流通股本
9.95亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
巨子生物股票表现良好,源于胶原蛋白产品的强劲实力
南方财富网 · 16:43
巨子生物股票表现良好,源于胶原蛋白产品的强劲实力
张坤隐形重仓股大变动!去年下半年新进、清仓这些公司
格隆汇 · 13:37
张坤隐形重仓股大变动!去年下半年新进、清仓这些公司
隐形重仓股出炉!张坤:大力出奇迹”和“乌鸡变凤凰”已经过去
智通财经 · 10:02
隐形重仓股出炉!张坤:大力出奇迹”和“乌鸡变凤凰”已经过去
巨子生物(02367)全年业绩超出预期,期待注射产品进展
中信建投 · 03-28 17:14
巨子生物(02367)全年业绩超出预期,期待注射产品进展
巨子生物(02367.HK):大单品方法论初显 看好妆械协同发展
华创证券 · 03-28 17:11
巨子生物(02367.HK):大单品方法论初显 看好妆械协同发展
巨子生物03月28日主力资金流出182万元 连续3日减仓
自选股智能写手 · 03-28 16:15
巨子生物03月28日主力资金流出182万元 连续3日减仓
巨子生物(02367)品牌及渠道调整驱动2024年高速增长
浦银国际证券 · 03-28 12:17
巨子生物(02367)品牌及渠道调整驱动2024年高速增长
巨子生物(02367)核心单品驱动高增长,23年业绩略超预期
招商证券 · 03-28 10:17
巨子生物(02367)核心单品驱动高增长,23年业绩略超预期
巨子生物2023年营收增长49%,可复美贡献八成营收
和讯网 · 03-27 20:56
巨子生物2023年营收增长49%,可复美贡献八成营收
年报里的中国经济|巨子生物2023年毛利下降至83.6%,可复美单品牌贡献近八成营收
21世纪经济报道 · 03-27 20:00
年报里的中国经济|巨子生物2023年毛利下降至83.6%,可复美单品牌贡献近八成营收
巨子生物(02367)2023年年报点评:全年业绩超预期,产品矩阵持续丰富
国元证券 · 03-27 14:14
巨子生物(02367)2023年年报点评:全年业绩超预期,产品矩阵持续丰富
【券商聚焦】德邦证券维持巨子生物(02367)“买入”评级 指其未来拟深化胶原蛋白龙头地位
金吾财讯 · 03-27 14:08
【券商聚焦】德邦证券维持巨子生物(02367)“买入”评级 指其未来拟深化胶原蛋白龙头地位
【券商聚焦】财通证券维持巨子生物(02367)“增持”评级 指医美管线有望年内落地开启第二曲线
金吾财讯 · 03-27 13:54
【券商聚焦】财通证券维持巨子生物(02367)“增持”评级 指医美管线有望年内落地开启第二曲线
巨子生物(2367.HK):业绩超预期 持续发力线上渠道
招银国际 · 03-27 11:31
巨子生物(2367.HK):业绩超预期 持续发力线上渠道
《大行报告》汇丰研究升巨子生物(02367.HK)目标价至52.8元 增长续闪耀整个行业
阿斯达克财经 · 03-27 11:13
《大行报告》汇丰研究升巨子生物(02367.HK)目标价至52.8元 增长续闪耀整个行业
巨子生物(2367.HK)2023年年报点评:可复美明星单品增势强劲 看好胶原蛋白“医美级”业务发展前景
光大证券 · 03-27 10:21
巨子生物(2367.HK)2023年年报点评:可复美明星单品增势强劲 看好胶原蛋白“医美级”业务发展前景
巨子生物(02367)可复美带动收入业绩高增,净利率保持高位
中邮证券 · 03-27 10:17
巨子生物(02367)可复美带动收入业绩高增,净利率保持高位
巨子生物(02367)2023年归母净利润+45%,重组胶原龙头再创佳绩
开源证券 · 03-27 09:19
巨子生物(02367)2023年归母净利润+45%,重组胶原龙头再创佳绩
巨子生物(02367.HK)2023年年报点评:全球重组胶原领导者 核心单品持续放量
东吴证券 · 03-27 07:21
巨子生物(02367.HK)2023年年报点评:全球重组胶原领导者 核心单品持续放量
【东吴商社吴劲草团队】巨子生物2023年年报点评:全球重组胶原领导者,核心单品持续放量
草叔消费升级研究 · 03-26 22:32
【东吴商社吴劲草团队】巨子生物2023年年报点评:全球重组胶原领导者,核心单品持续放量
加载更多
公司概况
公司名称:
巨子生物
所属市场:
SEHK
上市日期:
--
主营业务:
巨子生物控股有限公司是一家中国的投资控股公司。该公司通过其子公司主要从事基于生物活性材料的美容和健康产品的研发、生产和销售。该公司的主要产品包括功能性护肤品和医用敷料,其产品的关键生物活性成分为重组胶原蛋白。该公司还开发和生产基于人参皂苷技术的稀有功能食品。该公司主要在国内市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":42.55,"timestamp":1711613283016,"preClose":42.55,"halted":0,"volume":1918976,"delay":0,"floatShares":995000000,"shares":995000000,"eps":1.6039741,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":0,"latestTime":"03-28 16:08:03","open":43,"high":43,"low":41.7,"amount":81467982,"amplitude":0.030552,"askPrice":42.55,"askSize":60000,"bidPrice":42.5,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":1.596392353715037,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1667491200000,"adjPreClose":42.55,"dividendRate":0.011147,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":0.4814544391119072,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"2423437026","title":"巨子生物股票表现良好,源于胶原蛋白产品的强劲实力","url":"https://stock-news.laohu8.com/highlight/detail?id=2423437026","media":"南方财富网","top":-1,"share":"https://www.laohu8.com/m/news/2423437026?lang=zh_cn&edition=full","pubTime":"2024-03-29 16:43","pubTimestamp":1711701810,"startTime":"0","endTime":"0","summary":"巨子生物在重组胶原蛋白行业的 综合 实力和领先地位得到进一步夯实。目前,巨子生物旗下可复美、可丽金品牌表现亮眼,明星单品维持强势,为公司业绩增长带来动力。可复美为肌肤问题提供解决方案的专业护理品牌,以重组胶原蛋白为成分,以修护肌肤问题为导向,专注肌肤科学护理研究十余年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032916502787c48ccf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032916502787c48ccf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2423890754","title":"张坤隐形重仓股大变动!去年下半年新进、清仓这些公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2423890754","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2423890754?lang=zh_cn&edition=full","pubTime":"2024-03-29 13:37","pubTimestamp":1711690656,"startTime":"0","endTime":"0","summary":"张坤现身回答:高质量发展年代,投资思路应该如何变化!","market":"us","thumbnail":"https://img3.gelonghui.com/d6598-ddeee49d-5c0e-490d-9c6f-4bc32fd36ed4.jpg?guru_height=854&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/d6598-ddeee49d-5c0e-490d-9c6f-4bc32fd36ed4.jpg?guru_height=854&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/713817","is_publish_highlight":false,"gpt_icon":0},{"id":"2423109165","title":"隐形重仓股出炉!张坤:大力出奇迹”和“乌鸡变凤凰”已经过去","url":"https://stock-news.laohu8.com/highlight/detail?id=2423109165","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2423109165?lang=zh_cn&edition=full","pubTime":"2024-03-29 10:02","pubTimestamp":1711677761,"startTime":"0","endTime":"0","summary":"在粗放增长年代时常出现的“大力出奇迹”和“乌鸡变凤凰”将更难复制,企业的经营需要更加精细化,需要用更加严格和细致的标准去评估投资标的。其中规模最大的产品是易方达蓝筹精选,截至2023年四季度末,基金资产净值为417.38亿元。由于前十重仓股已在2023年四季报中做过披露,因此此次年报的看点落在2023年报披露的隐形重仓股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096103.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422547781","title":"巨子生物(02367)全年业绩超出预期,期待注射产品进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422547781","media":"中信建投","top":-1,"share":"https://www.laohu8.com/m/news/2422547781?lang=zh_cn&edition=full","pubTime":"2024-03-28 17:14","pubTimestamp":1711617259,"startTime":"0","endTime":"0","summary":"核心观点公司发布2023年度业绩公告,收入及利润端保持快速增长,业绩超出此前预期。功效性护肤品增长快速拉动营收增长,可复美放量超预期,品类拓展成效显著。负面新闻及产品事件对公司品牌影响的风险:公司目前主要收入来自可复美及可丽金两大品牌,负面事件对品牌经营可能造成一定影响。单一经销商依赖的风险;不良医疗事件可能对行业造成冲击超出预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281730528b6d3320&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281730528b6d3320&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422866154","title":"巨子生物(02367.HK):大单品方法论初显 看好妆械协同发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422866154","media":"华创证券","top":-1,"share":"https://www.laohu8.com/m/news/2422866154?lang=zh_cn&edition=full","pubTime":"2024-03-28 17:11","pubTimestamp":1711617107,"startTime":"0","endTime":"0","summary":"23 下半年营收占比54.4%为19.2 亿元,同比增长39.1%;归母净利润7.85 亿元,同比增长39.0%,毛利率83.2%,归母净利率41.6%。可复美大单品方法论驱动增长,产品矩阵进一步丰富。可丽金平稳过渡,24 年有望迎来快速增长。23 年可丽金渠道调整、产品开发和孵化占主要地位,营收6.2 亿元,同比基本持平,营收占比17.5%。投资建议:公司23 年线上大单品策略初显,产品力+渠道+运营协同发展思路清晰,化妆品业务在可复美和可丽金两大品牌下增长可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281711508b6d21dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281711508b6d21dd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422215860","title":"巨子生物03月28日主力资金流出182万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2422215860","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422215860?lang=zh_cn&edition=full","pubTime":"2024-03-28 16:15","pubTimestamp":1711613709,"startTime":"0","endTime":"0","summary":"03月28日,巨子生物股价收平报42.55元,成交金额8146万元,换手率0.19%,振幅3.06%,量比0.48。巨子生物今日主力资金净流出182万元,连续3日净流出,上一交易日主力净流出662万元,今日环比减少72.51%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为58.33%,平均跌幅为1.24%。该股近5个交易日下跌1.50%,主力资金累计净流出1434万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入157万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281615148b6ce9f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281615148b6ce9f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422853181","title":"巨子生物(02367)品牌及渠道调整驱动2024年高速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422853181","media":"浦银国际证券","top":-1,"share":"https://www.laohu8.com/m/news/2422853181?lang=zh_cn&edition=full","pubTime":"2024-03-28 12:17","pubTimestamp":1711599440,"startTime":"0","endTime":"0","summary":"巨子生物当前的线上收入占比仍低于同业,我们认为,在巨子生物化妆品收入占比提升以及可丽金品牌收入提速的带动下,公司线上收入占比仍有提升空间,将驱动整体收入保持快速增长。我们预计,在可复美保持快速增长的基础上,随着可丽金产品和渠道调整愈加完善,线上渠道销售增长,可丽金2024年收入增速有望赶超可复美。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281235518b6c2dbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281235518b6c2dbd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422218650","title":"巨子生物(02367)核心单品驱动高增长,23年业绩略超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2422218650","media":"招商证券","top":-1,"share":"https://www.laohu8.com/m/news/2422218650?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:17","pubTimestamp":1711592275,"startTime":"0","endTime":"0","summary":"核心单品驱动功效性护肤品营收高增,营销推广力度加大&渠道精细化运营驱动线上直销快速增长。核心单品驱动功效性护肤品持续高增,线上直销增速亮眼。可复美依旧贡献主要增量,核心单品胶原棒、医用敷料高速增长,胶原修护、净痘清颜等产品系列持续扩展。2023年公司毛利率为83.6%,同比下滑0.8pct。综合影响下,公司2023年净利率为41.2%,同比下滑1.2pct;经调整净利率为41.7%,同比下滑3.0pct,盈利能力略有下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281142178b6bf469&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281142178b6bf469&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422997493","title":"巨子生物2023年营收增长49%,可复美贡献八成营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2422997493","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2422997493?lang=zh_cn&edition=full","pubTime":"2024-03-27 20:56","pubTimestamp":1711544175,"startTime":"0","endTime":"0","summary":" 上市第二年,巨子生物再次实现营收净利双增长。据财报显示,2023年该公司的销售及经销开支增长超过五成。巨子生物手握两大现金奶牛,即可复美和可丽金。而可丽金的营收为6.17亿元,同比下降了2.9%,占2023年总营收的17.5%。据悉,可复美在2019-2021年间占总收入比重分别为80.6%、82.4%、91.7%。而2022年,可复美实现的营收为16.13亿元,占全年总营收的68.2%。据财报显示,2023年巨子生物通过DTC店铺的在线直销收入为21.55亿元,较去年同期增长了77.5%,占当年总收入的61.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272126448b69d74d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272126448b69d74d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422993060","title":"年报里的中国经济|巨子生物2023年毛利下降至83.6%,可复美单品牌贡献近八成营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2422993060","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2422993060?lang=zh_cn&edition=full","pubTime":"2024-03-27 20:00","pubTimestamp":1711540800,"startTime":"0","endTime":"0","summary":"近日,巨子生物发布2023年财报称,实现营业收入35.24亿元,同比2022年的23.64亿元上涨了49%;净利润为14.48亿元,同比增长44.6%。对此,巨子生物解释称,主要由于销售成本增加及产品类型扩充。财报显示,2023年,巨子生物的销售及经销开支高达11.65亿元,同比上涨了64.8%。凭借可复美与可丽金两大主力品牌销量上涨,巨子生物营收进一步高走。值得一提的是,该公司2023年毛利率为83.6%,同比下降0.8个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032720045887bc3dd4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032720045887bc3dd4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422931243","title":"巨子生物(02367)2023年年报点评:全年业绩超预期,产品矩阵持续丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2422931243","media":"国元证券","top":-1,"share":"https://www.laohu8.com/m/news/2422931243?lang=zh_cn&edition=full","pubTime":"2024-03-27 14:14","pubTimestamp":1711520076,"startTime":"0","endTime":"0","summary":"事件:公司发布2023年年报。点评:全年业绩超预期,H2销售费用率明显优化2023年公司实现营业收入35.24亿元,同比增长49.05%,实现归属母公司净利润14.52亿元,同比增长44.88%。23年牵头制定首个重组胶原蛋白团标,今年3月15日发布行业首个“透明承诺”,持续夯实重组胶原蛋白赛道领先地位。可丽金实现收入6.17亿元,同比基本持平,赋能紧致系列明星单品如嘭嘭次抛、大膜王持续热销,胶卷眼霜、胶卷面霜相继上新,其中胶卷面霜3月登顶天猫新品榜TOP1。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032714303287bb06fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032714303287bb06fb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422360069","title":"【券商聚焦】德邦证券维持巨子生物(02367)“买入”评级 指其未来拟深化胶原蛋白龙头地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2422360069","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2422360069?lang=zh_cn&edition=full","pubTime":"2024-03-27 14:08","pubTimestamp":1711519709,"startTime":"0","endTime":"0","summary":"金吾财讯 | 德邦证券发研报指,巨子生物 23年实现营业收入35.24亿/+49.0%,归母净利润14.52亿/+44.9%,收入、利润均超预期,主因电商渠道放量增长。净利率:23年为41.1%/-1.27pcts,23H1/23H2分别为41.5%/40.8%,整体保持稳定。该行指,巨子生物不断强化研发投入夯实基本盘,形成两大品牌+多子品牌的多元架构模式,布局全渠道销售网络,未来拟持续强化研发、丰富产品矩阵,深化胶原蛋白龙头地位,预计24-26年营收为46.64/59.02/72.47亿,净利润为17.64/22.00/27.01亿,对应PE为22X/18X/14X,维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934167","is_publish_highlight":false,"gpt_icon":0},{"id":"2422393548","title":"【券商聚焦】财通证券维持巨子生物(02367)“增持”评级 指医美管线有望年内落地开启第二曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2422393548","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2422393548?lang=zh_cn&edition=full","pubTime":"2024-03-27 13:54","pubTimestamp":1711518872,"startTime":"0","endTime":"0","summary":"金吾财讯 | 财通证券发研报指,巨子生物 发布23年业绩公告。该行续指,公司作为重组胶原龙头企业,主品牌可复美高质量推新&品牌心智强化实现高增,医美管线有望年内落地开启第二曲线。维持“增持”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZDJiMDMxMTQ0NzYwOTE1MWRjNWM4ZTAxY2ZiMjQwNjM2MTY3ODIyMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDJiMDMxMTQ0NzYwOTE1MWRjNWM4ZTAxY2ZiMjQwNjM2MTY3ODIyMw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934163","is_publish_highlight":false,"gpt_icon":0},{"id":"2422989483","title":"巨子生物(2367.HK):业绩超预期 持续发力线上渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2422989483","media":"招银国际","top":-1,"share":"https://www.laohu8.com/m/news/2422989483?lang=zh_cn&edition=full","pubTime":"2024-03-27 11:31","pubTimestamp":1711510297,"startTime":"0","endTime":"0","summary":"可丽金在2023 年继续进行渠道调整,创客村的经销收入持续下降,因此2023 年可丽金收入基本持平,为6.2 亿元。线上渠道快速拓展,直销占比持续提升。2023 年直销收入同比增长72.7%至24.2 亿元,收入占比同比增长9.4 个百分点至68.7%。2023 年巨子生物销售费用率为33.0%,同比增长3.2 个百分点,我们认为主要是线上销售占比提升所致,预计线上销售费用率较为稳定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032711314087ba6c31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032711314087ba6c31&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422898609","title":"《大行报告》汇丰研究升巨子生物(02367.HK)目标价至52.8元 增长续闪耀整个行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2422898609","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422898609?lang=zh_cn&edition=full","pubTime":"2024-03-27 11:13","pubTimestamp":1711509180,"startTime":"0","endTime":"0","summary":"汇丰环球研究发表报告指,巨子生物(02367.HK) 去年增长及毛利表现有惊喜,集团亦派发特别股息,令总派息比率达61%。汇丰研究上调巨子生物股份目标价,由49.9元升至52.8元,维持“买入”评级,认为其增长继续闪耀整个行业。另外,受强劲的产品周期支持,该行同时上调集团收入预测2.6%至3.3%,盈利预测则大致保持不变。(ek/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-26 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20221209170600402_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20221209170600402_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337569/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422600145","title":"巨子生物(2367.HK)2023年年报点评:可复美明星单品增势强劲 看好胶原蛋白“医美级”业务发展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2422600145","media":"光大证券","top":-1,"share":"https://www.laohu8.com/m/news/2422600145?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:21","pubTimestamp":1711506118,"startTime":"0","endTime":"0","summary":"事件:公司发布2023 年年报,2023 年实现营业收入35.24 亿元,同比增长49.0%;归母净利润为14.52 亿元,同比增长44.9%;经调整净利润为14.69 亿元,同比增长39.0%。截至2023 年12 月末,公司已获授权及申请中专利达到93 项,重组胶原蛋白分子库中拥有40 余种胶原分子,拥有超过100 个在研项目。目前公司的估值水平较低,维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271022018b67b33d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271022018b67b33d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422986311","title":"巨子生物(02367)可复美带动收入业绩高增,净利率保持高位","url":"https://stock-news.laohu8.com/highlight/detail?id=2422986311","media":"中邮证券","top":-1,"share":"https://www.laohu8.com/m/news/2422986311?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:17","pubTimestamp":1711505842,"startTime":"0","endTime":"0","summary":"事件回顾公司2023年实现收入35.2亿元,同增49%,实现归母净利润为14.5亿元,同增44.9%,每股基本盈利为1.49元,每股摊薄盈利为1.48元。公司收入业绩均超预期。事件点评次抛等产品带动可复美高增,医用敷料保持稳健增长。毛利率受产品结构等因素影响下降,渠道结构带动销售费用率提升,净利率保持高位。综合,公司2023年归母净利率下降1.9pct至41.2%,净利率保持高位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032711103087ba5514&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032711103087ba5514&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422602963","title":"巨子生物(02367)2023年归母净利润+45%,重组胶原龙头再创佳绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2422602963","media":"开源证券","top":-1,"share":"https://www.laohu8.com/m/news/2422602963?lang=zh_cn&edition=full","pubTime":"2024-03-27 09:19","pubTimestamp":1711502340,"startTime":"0","endTime":"0","summary":"事件:2023年归母净利润+44.9%,重组胶原蛋白龙头展现强α公司发布年报:2023年实现营收35.24亿元,归母净利润14.52亿元,行业承压背景下增长亮眼。公司是重组胶原蛋白龙头,护肤业务高增、III类械产品落地在即,估值合理,维持“买入”评级。此外,2023年公司销售/管理/研发费用率分别为33.0%/2.7%/2.1%,同比分别+3.2pct/-2.0pct/+0.3pct,线上直销渠道扩张带动销售费用率小幅提升。研发端:2023年新获专利13项,分子库中已储备超40种胶原分子,保持领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032710011787ba058d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032710011787ba058d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422674308","title":"巨子生物(02367.HK)2023年年报点评:全球重组胶原领导者 核心单品持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2422674308","media":"东吴证券","top":-1,"share":"https://www.laohu8.com/m/news/2422674308?lang=zh_cn&edition=full","pubTime":"2024-03-27 07:21","pubTimestamp":1711495302,"startTime":"0","endTime":"0","summary":"可复美实现高增,妆品化更进一步,全球重组胶原领导者:分品牌:2023 年可复美/可丽金分别实现营收27.9/6.2 亿元,可复美+72.9%,可丽金基本持平,可复美/可丽金营收占比分别为79.1%/17.5%。2024 年3月,欧睿国际发布声明认定巨子生物为全球重组胶原蛋白领导者。2024 年以来,可复美陆续上新胶原冻膜、焦点面霜等新品,可丽金上新胶卷眼霜、胶卷面霜等新品。盈利预测与投资评级:公司是我国重组胶原领域引领者,品牌力和产品力领先,未来拓展肌肤焕活可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270721468b671f3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270721468b671f3e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422298641","title":"【东吴商社吴劲草团队】巨子生物2023年年报点评:全球重组胶原领导者,核心单品持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2422298641","media":"草叔消费升级研究","top":-1,"share":"https://www.laohu8.com/m/news/2422298641?lang=zh_cn&edition=full","pubTime":"2024-03-26 22:32","pubTimestamp":1711463520,"startTime":"0","endTime":"0","summary":"团队首席吴劲草新书,已于2022年出版《吴劲草讲消费行业:发现生活中的长线大牛股》更全更系统的消费研究框架,欢迎扫码了解!公司23年营收、业绩增速均超此前市场预期。2024年3月,欧睿国际发布声明认定巨子生物为全球重组胶原蛋白领导者。2024年以来,可复美陆续上新胶原冻膜、焦点面霜等新品,可丽金上新胶卷眼霜、胶卷面霜等新品。盈利预测与投资评级:公司是我国重组胶原领域引领者,品牌力和产品力领先,未来拓展肌肤焕活可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzIwMjU2Nzg0MQ==&mid=2247544167&idx=2&sn=f56ff49e60fa01efc9738d5baadae240&chksm=9714f665930ae19f0e3f192b701ed79ba9732422830ba5c67f80df21a206e3670d146999d960&scene=0#rd","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":0.1852},{"period":"3month","weight":0.1952},{"period":"6month","weight":0.2533},{"period":"1year","weight":-0.0869},{"period":"ytd","weight":0.1952}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家中国的投资控股公司。该公司通过其子公司主要从事基于生物活性材料的美容和健康产品的研发、生产和销售。该公司的主要产品包括功能性护肤品和医用敷料,其产品的关键生物活性成分为重组胶原蛋白。该公司还开发和生产基于人参皂苷技术的稀有功能食品。该公司主要在国内市场开展其业务。","exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}